drugset / Trial / NCT04955743
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 2, Simon's 2-stage designed study with 2 cohorts of anti-PD-1/PD-L1 experienced patients with untreated brain metastases: 1) melanoma and 2) renal cell carcinoma (RCC).
Timeline
- Start
- 2022-02-09
- Primary completion
- 2025-05-28
- Completion
- 2025-05-28
Outcome
Outcome not reported
Stopped: “Lack of activity in the drugs”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 20 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |